No Difference in Efficacy Between Ofatumumab, Rituximab in DLBCL

For treatment in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), there is no difference in efficacy between ofatumumab or rituximab when either is paired with cisplatin, cytarabine, and dexamethasone (DHAP) salvage therapy following autologous stem-cell transplantation (ASCT), according to a study published in the Journal of Clinical Oncology.¹

Researchers evaluated 447 adult patients who had CD20-positive DLBCL who were refractory to first-line treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or experienced first relapse. The median age of the observed patients was 57 years; 63% had stage 3 or 4 disease.

The response rate was 38% for patients treated with ofatumumab and 42% for patients treated with rituximab. Post study-treatment ASCT was completed for 74 patients treated with ofatumumab (33%) and 83 patients treated with rituximab (37%).

Progression-free survival at 2 years was 24% for patients treated with ofatumumab and 26% for those treated with rituximab. Event-free survival at 2 years was 16% with ofatumumab and 18% for rituximab; overall survival at 2 years was 41% with ofatumumab and 38% with rituximab.

“Characteristics of patients who enrolled in our study are representative of the typical patients who are encountered in daily practice who have experienced failure of first-line R-CHOP treatment and are deemed eligible for ASCT,” the authors noted.

Reference

1. van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2016 Dec 28. doi: 10.1200/JCO.2016.69.0198 [Epub ahead of print]